Drug Profile


Alternative Names: DAG for Injection; Dianhydrodulcitol; Diepoxydulcitol; Diepoxygalactitol; NSC-1323313; VAL-083

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator DelMar Pharmaceuticals
  • Developer DelMar Pharmaceuticals; Guangxi Wuzhou Pharmaceutical; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Ethylene glycols; Small molecules
  • Mechanism of Action Alkylating agents; Cell cycle inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Ovarian cancer; Medulloblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic myeloid leukaemia; Lung cancer

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Lung cancer
  • Phase III Glioblastoma
  • Clinical Phase Unknown Haematological malignancies; Solid tumours
  • Preclinical Medulloblastoma; Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 24 Jul 2017 Phase-III clinical trials in Glioblastoma (Recurrent, Second-line therapy or greater) in USA (IV) (NCT03149575)
  • 24 Jul 2017 The Human Genetic Resources Administration of China approves the application to initiate a phase II trial in Glioblastoma multiforme
  • 22 Jun 2017 The Institutional Review Board (IRB) grants approval to DelMar to conduct the STAR-3 (phase III) trial for dianhydrogalactito in Glioblastoma multiforme in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top